Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12410695 | 0.78 | APLNR (0.32) | ADORA2AADORA1 | |
| SCHEMBL19501372 | 0.76 | HPGD (0.34) | HSD17B10ADORA2AADORA1KDM4E | |
| SCHEMBL24450020 | 0.76 | ESR1 (0.33) | ADORA2AADORA1 | |
| SCHEMBL14072327 | 0.73 | TNKS (0.30) | — | |
| SCHEMBL2114223 | 0.72 | — | — | |
| SCHEMBL506044 | 0.71 | ADORA2A (0.38) | ADORA2AADORA1 | |
| SCHEMBL11169191 | 0.71 | — | — | |
| SCHEMBL20635123 | 0.71 | KDM4E (0.34) | KDM4E | |
| SCHEMBL31691880 | 0.69 | ADORA2A (0.34) | ADORA2AADORA1 | |
| SCHEMBL2116411 | 0.68 | HSD17B10 (0.34) | HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2025-04-10 | — | — | US | disclosed |
| US-11981667-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-05-14 | — | — | US | disclosed |
| CN-111132974-B | Sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| US-11465992-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2022-10-11 | — | — | US | disclosed |
| US-20220162161-A1 | Novel compounds and their uses as thyroid hormone receptor agonists | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| EP-3978489-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3661925-B1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2021-11-24 | — | — | EP | disclosed |
| EP-3661925-B1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2021-11-24 | — | — | EP | disclosed |
| US-20200361895-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-11-19 | — | — | US | disclosed |
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| CN-111132974-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-110914256-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-03-24 | — | — | CN | disclosed |
| WO-2019034686-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019008025-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| US-8158652-B2 | 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20080269287-A1 | Substituted Pyridone Derivative | MSD K.K. (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1820797-A1 | SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361895-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | HSD17B10 2027/4885ADORA2A 696/4885ADORA1 327/4885 |
| US-20220162161-A1 | Novel compounds and their uses as thyroid hormone receptor agonists | THRA, THRB, TSHR | HSD17B10 200/4885ADORA2A 1545/4885ADORA1 799/4885 |
| US-20080269287-A1 | Substituted Pyridone Derivative | HRH3, HRH4, HRH1 | HSD17B10 504/4885ADORA2A 379/4885ADORA1 31/4885 |
| US-11981667-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, PYCARD | HSD17B10 2391/4885ADORA2A 974/4885ADORA1 335/4885 |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | HSD17B10 2390/4885ADORA2A 855/4885ADORA1 302/4885 |
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | HSD17B10 2390/4885ADORA2A 855/4885ADORA1 302/4885 |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | HSD17B10 2220/4885ADORA2A 776/4885ADORA1 284/4885 |
| US-11465992-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, PYCARD | HSD17B10 2381/4885ADORA2A 894/4885ADORA1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.